Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 4/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.47 |
| ▸ | HTR3A | P46098 | 4/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.47 |
| ▸ | HTR3B | O95264 | 3/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13092430 | 0.84 | ADRB1 (0.61) | ACVR1HTR1AHTR7HTR2BHTR6 | |
| SCHEMBL13118650 | 0.84 | CHRNB2 (0.57) | ACVR1CHRNB2CHRNA4ADRB1HTR3A | |
| SCHEMBL1200127 | 0.81 | PLD1 (0.56) | HTR1AHTR7CHRNB2CHRNA4ADRB1 | |
| SCHEMBL13092429 | 0.81 | MAPKAPK2 (0.48) | ACVR1CHRNB2CHRNA4ADRB1HTR3A | |
| SCHEMBL13092435 | 0.80 | ADRB1 (0.64) | ACVR1HTR1AHTR7HTR2BHTR6 | |
| SCHEMBL13092428 | 0.80 | ADRB1 (0.47) | ACVR1CHRNB2CHRNA4ADRB1HTR3A | |
| SCHEMBL943026 | 0.79 | HTR7 (0.70) | ACVR1HTR1AHTR7HTR2BHTR6 | |
| SCHEMBL21956060 | 0.79 | CETP (0.60) | ACVR1CHRNB2CHRNA4ADRB1HTR3A | |
| SCHEMBL13092427 | 0.79 | ACVR1 (0.52) | ACVR1CHRNB2CHRNA4ADRB1HTR3A | |
| Hydrochloric Acid SCHEMBL28605924 | 0.79 | ADRB2 (0.53) | ACVR1CHRNB2CHRNA4ADRB1HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| EP-2170893-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156739-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | ACVR1 3363/4885HTR1A 3948/4885HTR7 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.